Zevra Therapeutics, Inc. (ZVRA) stock
ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.28−0.12 (-1.28%)
Close on Nov 18, 2026Market cap $551.08MP/E 10.0Yield –
Zevra Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Zevra Therapeutics's total assets was $302.71M at Jun 30, 2026. For fiscal 2025 it was $284.73M, up 59.8% from the year before. Over ten years it grew 18.0% a year on average. The highest annual figure on record is $284.73M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $284.73M | +59.8% |
| FY2024 | Dec 31, 2024 | $178.13M | +3.4% |
| FY2023 | Dec 31, 2023 | $172.33M | +49.4% |
| FY2022 | Dec 31, 2022 | $115.34M | -13.2% |
| FY2021 | Dec 31, 2021 | $132.94M | +1086.0% |
| FY2020 | Dec 31, 2020 | $11.21M | +6.7% |
| FY2019 | Dec 31, 2019 | $10.51M | -60.7% |
| FY2018 | Dec 31, 2018 | $26.75M | -49.0% |
| FY2017 | Dec 31, 2017 | $52.46M | -38.2% |
| FY2016 | Dec 31, 2016 | $84.89M | +55.5% |
| FY2015 | Dec 31, 2015 | $54.59M | +298.1% |
| FY2014 | Dec 31, 2014 | $13.71M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $302.71M | +18.1% |
| Q1 FY2026 | Mar 31, 2026 | $278.58M | +61.3% |
| Q4 FY2025 | Dec 31, 2025 | $284.73M | +59.8% |
| Q3 FY2025 | Sep 30, 2025 | $270.12M | +41.0% |
| Q2 FY2025 | Jun 30, 2025 | $256.28M | +77.5% |
| Q1 FY2025 | Mar 31, 2025 | $172.71M | +14.2% |
| Q4 FY2024 | Dec 31, 2024 | $178.13M | +3.4% |
| Q3 FY2024 | Sep 30, 2024 | $191.55M | +37.8% |
| Q2 FY2024 | Jun 30, 2024 | $144.41M | +36.9% |
| Q1 FY2024 | Mar 31, 2024 | $151.28M | +41.9% |
| Q4 FY2023 | Dec 31, 2023 | $172.33M | +49.4% |
| Q3 FY2023 | Sep 30, 2023 | $138.98M | +16.3% |
| Q2 FY2023 | Jun 30, 2023 | $105.52M | -15.1% |
| Q1 FY2023 | Mar 31, 2023 | $106.60M | -15.2% |
| Q4 FY2022 | Dec 31, 2022 | $115.34M | -13.2% |
| Q3 FY2022 | Sep 30, 2022 | $119.55M | -12.9% |
| Q2 FY2022 | Jun 30, 2022 | $124.26M | -10.5% |
| Q1 FY2022 | Mar 31, 2022 | $125.71M | +39.0% |
| Q4 FY2021 | Dec 31, 2021 | $132.94M | +1086.0% |
| Q3 FY2021 | Sep 30, 2021 | $137.19M | +1124.4% |
| Q2 FY2021 | Jun 30, 2021 | $138.80M | +1025.9% |
| Q1 FY2021 | Mar 31, 2021 | $90.44M | +917.8% |
| Q4 FY2020 | Dec 31, 2020 | $11.21M | +6.7% |
| Q3 FY2020 | Sep 30, 2020 | $11.20M | -13.1% |
| Q2 FY2020 | Jun 30, 2020 | $12.33M | -5.2% |
| Q1 FY2020 | Mar 31, 2020 | $8.89M | -55.3% |
| Q4 FY2019 | Dec 31, 2019 | $10.51M | -60.7% |
| Q3 FY2019 | Sep 30, 2019 | $12.89M | -31.2% |
| Q2 FY2019 | Jun 30, 2019 | $13.01M | -61.7% |
| Q1 FY2019 | Mar 31, 2019 | $19.87M | -53.4% |
| Q4 FY2018 | Dec 31, 2018 | $26.75M | -49.0% |
| Q3 FY2018 | Sep 30, 2018 | $18.74M | -68.4% |
| Q2 FY2018 | Jun 30, 2018 | $34.00M | -50.8% |
| Q1 FY2018 | Mar 31, 2018 | $42.65M | -43.6% |
| Q4 FY2017 | Dec 31, 2017 | $52.46M | -38.2% |
| Q3 FY2017 | Sep 30, 2017 | $59.31M | -37.3% |
| Q2 FY2017 | Jun 30, 2017 | $69.05M | – |
| Q1 FY2017 | Mar 31, 2017 | $75.64M | – |
| Q4 FY2016 | Dec 31, 2016 | $84.89M | – |
| Q3 FY2016 | Sep 30, 2016 | $94.54M | – |
See a number that looks wrong?